DOI: 10.2337/db23-125-lb ISSN: 0012-1797

125-LB: Risk of Hypoglycemia as Measured by Continuous Glucose Monitoring in the Hospital Setting—An Observational Study

MOLLIE O'CONNOR, AMY SABEAN, BARBARA STEINER, HUI ZHENG, JOYCE YAN, ANNABELLE ASHLEY, NILLANI ANANDAKUGAN, MELISSA M. CALVERLEY, RACHEL BARTHOLOMEW, EVELYN GREAUX, STEVEN J. RUSSELL, MELISSA S. PUTMAN
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Background: Prospective studies investigating the occurrence of and risk factors for continuous glucose monitoring (CGM) detected hypoglycemia in the inpatient setting are limited.

Methods: In this prospective observational study, patients hospitalized on medical and surgical floors and undergoing fingerstick glucose monitoring wore blinded Dexcom G6Pro sensors. Participants with sensor readings <54mg/dL were identified after excluding erroneous readings from compression via manual review. Data from participant survey and chart review were analyzed chi square tests for categorical variables, and t test and Kruskal-Wallis test for continuous variables to identify predictors of hypoglycemia.

Results: CGM data were collected from 268 participants. At least one episode of CGM glucose <54 mg/dL occurred in 30 (11%). Participants with at least one episode of glucose <54mg/dL had longer hospital stay, lower A1c (but also lower hemoglobin level), and were more likely to have type 1 diabetes compared to those without hypoglycemia (Table 1). Forty-six (17%) had what appeared to be a false reading <70 mg/dL due to compression or artifact at least once.

Conclusion: CGM may be helpful in identifying hypoglycemia in hospitalized patients. Further research is needed to identify patient populations who may benefit from inpatient CGM monitoring for prevention of hypoglycemia.

Disclosure

M. O'connor: None. E. Greaux: None. S. J. Russell: Consultant; Beta Bionics, Inc., Senseonics, ConvaTec Inc., Employee; Beta Bionics, Inc., Stock/Shareholder; Beta Bionics, Inc. M. S. Putman: Consultant; Synspira Therapeutics, Other Relationship; Vertex Pharmaceuticals Incorporated, Research Support; Dexcom, Inc. A. Sabean: None. B. Steiner: Stock/Shareholder; Bristol-Myers Squibb Company. H. Zheng: None. J. Yan: None. A. Ashley: None. N. Anandakugan: None. M. M. Calverley: None. R. Bartholomew: None.

Funding

National Institutes of Health (R01DK119699-02S1, T32DK007028); Dexcom, Inc. (to M.O.)

More from our Archive